NutriBand Inc.NTRB
Price (close)
$8.99
Market cap
$109.3M
P/E
—
Revenue (TTM)
$1.6M
Net income
-$7.0M
Dividend yield
—
1-year total return
25.4%
Net margin
-430.4%
Revenue growth
-37.3%
Debt / equity
0.00x
What NutriBand Inc. does.
of transdermal pharmaceutical products. Our development pipeline primarily consists of transdermal products that are based on our proprietary
services through our subsidiaries Pocono Pharmaceuticals operating as Active Intelligence and 4P Therapeutics. Pocono Pharmaceuticals
provides contract manufacturing services for health, wellness and over-the-counter pharmaceutical customers and 4P Therapeutics performs
Revenue and profit, by fiscal year.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Revenue | $943,702 | $1.4M | $2.1M | $2.1M | $2.1M | $2.0M |
| Net income | -$2.9M | -$6.2M | -$4.5M | -$5.5M | -$10.5M | -$8.2M |
| Free cash flow | — | -$2.9M | -$3.1M | -$3.6M | -$4.7M | -$5.1M |
More on NTRB.
- NutriBand Inc. summary
- NutriBand Inc. financial statements
- NutriBand Inc. key metrics
- NutriBand Inc. health scores and style box
- NutriBand Inc. earnings
- NutriBand Inc. dividends
- NutriBand Inc. valuation
- NutriBand Inc. ownership and insiders
- NutriBand Inc. peers
Figures from NutriBand Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.